Aesica has entered a manufacturing partnership with Noramco to provide the UK market with an alternative source of codeine API. The two companies have formed an integrated value chain comprising raw material supply security, technical excellence, production facilities and regulatory expertise. Noramco, a global manufacturer and supplier of opiate-derived APIs, will sell codeine manufactured by Aesica through its European-based sales team.
 
The alliance involves a technical transfer for the manufacture of codeine phosphate from a patented poppy supplied by Noramco’s sister company, Tasmanian Alkaloids. According to the companies, the conversion of the extracted alkaloid to a finished API in a one-step process has led to a reduction in the environmental impact of the production process, creating an environmentally friendly produced and competitive product.
 
Dr. Robert Hardy, chief executive officer, Aesica said, “Although we already have experience in manufacturing controlled drugs, our aim was always to create a manufacturing alliance with another experienced API developer to enable us to establish a leading presence. We are determined that the new manufacturing process we have developed with Noramco will re-invigorate the controlled drug market in the UK creating added value for customers and drive future innovations.”
 
“We are excited to supply the UK and other world markets from Aesica and have had very good response thus far from customers seeking a secure, integrated source of codeine and controlled ingredients,” said Leslie Storms, vice president of global sales at Noramco.